09.17.15
The United States Patent & Trademark Office has issued two new patents Boston, Mass.-based InspireMD Inc., a developer of embolic prevention systems (EPS), neurovascular devices and thrombus management technologies
The patents are: US. Patent No. 9,132,26, titled "In Vivo Filter Assembly," and U.S. Patent No. 9,132,003, titled "Optimized Drug Eluting Stent Assembly."
The in-vivo filter assembly patent covers an assembly for filtering debris flow in a blood vessel. The optimized drug stent patent covers a stent assembly with the company's proprietary MicroNet technology that elutes a drug. MicroNet is a bio-stable mesh woven from a single strand of 20 micron polyethylene terephthalate.
The company’s primary products are theCGuard Embolic Prevention System (EPS) and the MGuard Prime EPS. The CGuard EPS uses the same MicroNet technology featured on the MGuard and MGuard Prime coronary Embolic Protection Systems. The CGuard EPS is designed to prevent peri-procedural and late embolization by trapping potential emboli against the arterial wall while maintaining excellent perfusion to the external carotid artery and branch vessels.
MGuard Prime EPS, integrated with MicroNet, is designed to trap and seal thrombus and ruptured plaque, preventing distal embolization. MGuard Prime is a cobalt chromium stent wrapped in MicroNet.
MGuard EPS and CGuard EPS are CE marked and are not yet approved for sale in the United States by the U.S. Food and Drug Administration.
To date, the company's patent rights in the United States include four issued patents and 10 pending applications. Foreign patent rights include 13 issued patents focused in Israel, Canada, and China, and 16 pending patent applications.
The patents are: US. Patent No. 9,132,26, titled "In Vivo Filter Assembly," and U.S. Patent No. 9,132,003, titled "Optimized Drug Eluting Stent Assembly."
The in-vivo filter assembly patent covers an assembly for filtering debris flow in a blood vessel. The optimized drug stent patent covers a stent assembly with the company's proprietary MicroNet technology that elutes a drug. MicroNet is a bio-stable mesh woven from a single strand of 20 micron polyethylene terephthalate.
The company’s primary products are theCGuard Embolic Prevention System (EPS) and the MGuard Prime EPS. The CGuard EPS uses the same MicroNet technology featured on the MGuard and MGuard Prime coronary Embolic Protection Systems. The CGuard EPS is designed to prevent peri-procedural and late embolization by trapping potential emboli against the arterial wall while maintaining excellent perfusion to the external carotid artery and branch vessels.
MGuard Prime EPS, integrated with MicroNet, is designed to trap and seal thrombus and ruptured plaque, preventing distal embolization. MGuard Prime is a cobalt chromium stent wrapped in MicroNet.
MGuard EPS and CGuard EPS are CE marked and are not yet approved for sale in the United States by the U.S. Food and Drug Administration.
To date, the company's patent rights in the United States include four issued patents and 10 pending applications. Foreign patent rights include 13 issued patents focused in Israel, Canada, and China, and 16 pending patent applications.